Human japanese ips
![human japanese ips human japanese ips](https://cdn.mainichi.jp/vol1/2017/08/31/20170831p2a00m0na010000p/6.jpg)
5 Technology and Development Team for Mammalian Genome Dynamics, RIKEN BioResource Research Center, 3-1-1 Koyadai, Tsukuba, Ibaraki, 305-0074, Japan.4 Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan Department of Tissue Biochemistry, Graduate School of Medicine and Frontier Biosciences, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.3 Department of Mechanical Systems Engineering, Faculty of Systems Design, Tokyo Metropolitan University, 1-1 Minami-Osawa, Hachioji, Tokyo, 192-0397, Japan.2 Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan Department of Tissue Biochemistry, Graduate School of Medicine and Frontier Biosciences, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.1 Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019. The clinical application of hESC/iPSC-NR may compromise host immune responses in allogenic transplantation. HES/iPSC-NR showed low immunogenicity as indicated by minimal HLA class I expression and little stimulatory potency of allogenic immune cells, hES/iPSC-NR also showed some immune-suppressive property mediated by TGFβ signaling. TGFβ2 was present in the hESC-NR culture medium as determined by ELISA and the immunosuppressive property was reversed by TGFβ antibody or TGFβ receptor antagonist. Furthermore, hESC/iPSC-NR tissue strongly suppressed the proliferation of PBMCs activated by CD3/CD28 agonist antibody or mixed PBMCs. No PBMCs proliferation was triggered by autologous iPSC-NR while a mild proliferation was observed in allogenic PBMCs using the iPSC established in our lab. In co-culture assay, hESC/iPSC-NR cell suspension activated allogenic T lymphocytes and natural killer (NK) cells moderately while hESC/iPSC as a tissue evoked no such responses. HESC-NR expressed neglectable level of HLA class I and II at any developmental stage from differentiation day 27 to 239. Immunosuppressive potency of hESC/iPSC-NR was also tested using PBMCs activated by agonistic CD3/CD28 antibody or mixed PBMCs of 5 donors.
![human japanese ips human japanese ips](https://www.ipscell.com/wp-content/uploads/2012/10/iPS-cell-headline-clip1.png)
The responses between autologous PBMCs and allogenic PBMCs against hiPSC-NR cell suspension was also compared. In immunogenicity analysis, the proliferative features of human PBMCs against hES/iPSC-NR as a tissue or enzymatically dissociated cells was evaluated by co-culture assay. The expression of Human Leukocyte Antigen (HLA) class I and II at different developmental stages of hES/iPSC-NR was first tested using flow cytometry and immunohistochemistry. The hESC (KhES-1 CRX::Venus) and the hiPSC (TLHD2) lines were differentiated into retinal tissue by SFEBq method. The purpose of this study is to examine the immunologic properties of hES/iPS-NR for future clinical application in allogeneic transplantation therapy. Although autologous transplantation is ideal, a donor-derived tissue from a patient with a disease-causing gene mutation is not adequate for therapeutic use. We previously showed a long term survival, maturation, and light responsiveness of human ES/iPSC-neural retina(NR) after transplantation to end-stage retinal degeneration animal models. ES/iPSC-retina transplantation is a promising treatment approach for Retinitis Pigmentosa.